While startups such as General Catalyst-backed Voy and Mumbai-based Metago are seeing higher demand from women, Elevate Now, backed by Tita...

"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating ...

India's regulatory hurdles slow down early-stage drug trials significantly. This complexity causes Indian companies to conduct crucial firs...

Novo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...

Novo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments...

Novo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmake...

Pharma stocks rose up to 4% as Novo Nordisk’s semaglutide patent nears expiry, raising expectations of cheaper generics in India. Strong gr...

Zydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide ...

Dr Reddy's Laboratories is poised to launch its generic semaglutide injection, potentially named Obeda, in India by March. This move antici...

Novo Nordisk has launched Ozempic in India at a competitive price, aiming to capture a significant share of the growing weight-loss market....

Danish drugmaker Novo Nordisk is set to launch its popular diabetes drug Ozempic in India this month. This move aims to capture a significa...

Indian drugmakers are adjusting prices for weight-loss injections after Novo Nordisk cut prices for its drug Wegovy. This move is prompting...

Novo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...

Biocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense local competition...

India's Biocon is seeking a Chinese partner to conduct clinical trials on generic versions of Novo Nordisk's popular diabetes drug Ozempic ...

Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in gen...